MS MT - Regulus Therapeutics VP Operations
| RGLSDelisted Stock | USD 8.16 0.01 0.12% |
Insider
MS MT is VP Operations of Regulus Therapeutics
| Phone | 858 202 6300 |
| Web | https://www.regulusrx.com |
Regulus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3423) % which means that it has lost $0.3423 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5382) %, meaning that it created substantial loss on money invested by shareholders. Regulus Therapeutics' management efficiency ratios could be used to measure how well Regulus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Regulus Therapeutics currently holds 274 K in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Regulus Therapeutics has a current ratio of 8.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Regulus Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MD MBA | ARS Pharmaceuticals | 57 | |
| Peter MD | Invivyd | N/A | |
| Rebecca Dabora | Invivyd | 65 | |
| MBA MBA | ARS Pharmaceuticals | 72 | |
| Laura Walker | Invivyd | 39 | |
| Eric Karas | ARS Pharmaceuticals | 52 | |
| Robert Bell | ARS Pharmaceuticals | N/A | |
| Kathleen CPA | ARS Pharmaceuticals | N/A | |
| Frederick Driscoll | Invivyd | 73 | |
| Elham PharmD | Invivyd | 54 | |
| David MBA | Invivyd | 48 | |
| MBA MS | ARS Pharmaceuticals | 56 | |
| Kyra Faircloth | Invivyd | N/A | |
| Brian MS | ARS Pharmaceuticals | 57 | |
| MSc MD | Invivyd | N/A | |
Management Performance
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 |
Regulus Therapeutics Leadership Team
Elected by the shareholders, the Regulus Therapeutics' board of directors comprises two types of representatives: Regulus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regulus. The board's role is to monitor Regulus Therapeutics' management team and ensure that shareholders' interests are well served. Regulus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regulus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MBA, CEO Director | ||
| MS MT, VP Operations | ||
| MS MD, Senior Regulatory | ||
| Christopher JD, General VP | ||
| Crispina CPA, Chief Officer | ||
| Denis Drygin, Chief Officer | ||
| Firuz Shakoori, Head CMC | ||
| MHS MD, Head President | ||
| Daniel Penksa, Principal Accounting Officer, Controller | ||
| Edmund Lee, Vice Medicine |
Regulus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regulus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | 500.99 M | |||
| Shares Outstanding | 69.23 M | |||
| Shares Owned By Insiders | 2.70 % | |||
| Shares Owned By Institutions | 82.87 % | |||
| Number Of Shares Shorted | 2.09 M | |||
| Price To Earning | (0.69) X | |||
| Price To Book | 8.19 X | |||
| Price To Sales | 7.43 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Regulus Stock
If you are still planning to invest in Regulus Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regulus Therapeutics' history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |